QUANTITY LIMIT CRITERIA

Similar documents
QUANTITY LIMIT CRITERIA. BROVANA (arformoterol tartrate) SEREVENT DISKUS (salmeterol) STRIVERDI RESPIMAT (olodaterol)

QUANTITY LIMIT CRITERIA

PHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 11/16/17 SECTION: DRUGS LAST REVIEW DATE: 11/16/17 LAST CRITERIA REVISION DATE: ARCHIVE DATE:

QUANTITY LIMIT CRITERIA

Select Inhaled Respiratory Agents

STEP THERAPY CRITERIA

STEP THERAPY CRITERIA

DURATION LIMIT CRITERIA ACETAMINOPHEN/ASPIRIN/IBUPROFEN CONTAINING OPIOID ANALGESICS (BRAND AND GENERIC) (acetaminophen and benzhydrocodone)

TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder

DURATION LIMIT WITH QUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA IMMEDIATE-RELEASE OPIOID ANALGESICS (BRAND AND GENERIC)*

Clinical Policy: Fluticasone/Salmeterol (Advair Diskus, Advair HFA) Reference Number: CP.PMN.31 Effective Date: 08/16 Last Review Date: 08/17

SHORT ACTING BETA 2 AGONISTS (SABA) Lisa Romard, RN, MSN, CPNP, ANP, AE-C

Inhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath.

See Important Reminder at the end of this policy for important regulatory and legal information.

First to Market or 505 (b)2 CMC Considerations IPAC-RS/UF Orlando Inhalation Conference Orlando, Florida

QUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA

MEDICAL PRIOR AUTHORIZATION

Formulary Medical Necessity Program

AIRDUO RESPICLICK (fluticasone-salmeterol) aerosol DULERA (mometasone furoate and formoterol fumarate dihydrate) aerosol

Nucala. Nucala (mepolizumab) Description

MANAGING ASTHMA. Nancy Davis, RRT, AE-C

Using Inhaled Corticosteroids as Needed for Asthma: giving patients relief or leaving them breathless?

Inhaled Corticosteroid Dose Comparison in Asthma

STRIVERDI RESPIMAT (olodaterol hcl) aerosol

STEP THERAPY WITH QUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA. AVINZA (morphine extended-release capsules)

Barr Laboratories, Inc. et al.; Withdrawal of Approval of 68 Abbreviated New Drug Applications

Carefirst.+.V Family of health care plans

JEOPARDY JEOPARDY JEOPARDY JEOPARDY JEOPARDY JEO RDY JEOPARDY JEOPARDY JEOPARDY JEOPARDY JEOPARDY

Effect of Study Design on Sample Size in Studies Intended to Evaluate Bioequivalence of Inhaled Short-Acting β-agonist Formulations

Anti-Migraine Agents

IL-5 Antagonists (IgG1 kappa) Fasenra (benralizumab) Nucala (mepolizumab) Description

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

How Orthodontic Benefits are Paid

Suboxone, Zubsolv, Bunavail (buprenorphine with naloxone sublingual tablets and film), Buprenorphine sublingual tablets

COPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor

DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL

reslizumab (Cinqair )

Carelirst.+.V Family of health care plans

Individual Select Preferred Dental

Oregon Health Plan prescription benefit updates

Pharmacy Medical Policy Asthma and Chronic Obstructive Pulmonary Disease Medication Management

Individual Select Preferred Dental

Advance in inhaler technique: changes in delivery devices, Authorized Generics, and Advance in technology for monitoring inhaler adherence

Treatment of Acute Asthma Exacerbations in Adults in the Primary Care or Urgent Care Setting Clinical Practice Guideline MedStar Health.

Diagnosis and Management of Asthma

Combination Beta2-Agonist/Corticosteroid Inhalers

Nucala (mepolizumab) Prior Authorization Protocol

Impact of a Comprehensive COPD Therapeutic Interchange Program on 30-Day Readmission Rates in Hospitalized Patients

See Important Reminder at the end of this policy for important regulatory and legal information.

Carefirst. +.V Family of health care plans

Combination Beta2-Agonist/Corticosteroid Inhalers Policy Number: Last Review: Origination: Next Review: Policy When Policy Topic is covered:

What You Need to Know about Metered-Dose Inhalers and the HFA Propellant

Embeda. Embeda (morphine sulfate and naltrexone hydrochloride) Description

A Visual Approach to Simplifying Respiratory Drug Regimens

Individual Select Dental HMO. Northern Virginia

Chronic Obstructive Pulmonary Disease

Provider Respiratory Inservice

Pharmacy Medical Necessity Guidelines: Migraine Medications

Pharmacist CE LESSON. Breathe easy: with asthma/copd 1 MAY 2016

and will be denied as not medically necessary** if not met. This criterion only applies to the initial

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 07/05/18 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:

Immediate Release Opioid Analgesics (Brand and Generic): Acute Pain Duration Limit with MME Limit and Post Limit Policy

Effect of Interval Between Actuations of Albuterol Hydrofluoroalkane Pressurized Metered-Dose Inhalers on Their Aerosol Characteristics

See Important Reminder at the end of this policy for important regulatory and legal information.

MEDICATION GUIDE. ADVAIR [ad vair] HFA 45/21 (fluticasone propionate 45 mcg and salmeterol 21 mcg) Inhalation Aerosol

Sumatriptan Injection (Imitrex / Alsuma / Sumavel / Zembrace)

MANAGEMENT OF ASTHMA SPRING Presented by:

A COPD medication delivery device option: an overview of the NEOHALER

Nancy Davis, RRT, AE-C

Class I Drugs Event Event ID: Product Type: Status: Date Terminated: Recall Initiation Date: Voluntary / Mandated: Center Classification Date:

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

Tocolytics. Tocolytics (terbutaline, magnesium sulfate injection) Description

A Visual Approach to Simplifying Respiratory Drug Regimens

See Important Reminder at the end of this policy for important regulatory and legal information.

Influenza Therapies. Considerations Prescription influenza therapies require prior authorization through pharmacy services.

A Visual Approach to Simplifying Respiratory Drug Regimens

Sumatriptan Tablets, Nasal Spray (Imitrex), Nasal Powder (Onzetra Xsail), sumatriptan and naproxen sodium (Treximet tablets)

FASENRA (benralizumab)

Asthma Coding Fact Sheet for Primary Care Pediatricians

See Important Reminder at the end of this policy for important regulatory and legal information.

Idaho DUR Board Meeting Minutes

MDI Bonanza. Dwayne Griffin, DO

Quarterly pharmacy formulary change notice

Aerospan (flunisolide)

Sumatriptan Tablets, Nasal Spray (Imitrex), Nasal Powder (Onzetra Xsail), sumatriptan and naproxen sodium (Treximet tablets)

See Important Reminder at the end of this policy for important regulatory and legal information.

2017 Dental Options BALTIMORE CITY PUBLIC SCHOOLS. Baltimore City Public Schools 2017 Dental Options C1

See Important Reminder at the end of this policy for important regulatory and legal information.

Morphine Sulfate Hydromorphone Oxymorphone

Sumatriptan Tablets, Nasal Spray (Imitrex), Nasal Powder (Onzetra Xsail), sumatriptan and naproxen sodium (Treximet tablets)

Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health

Dental Options 2018 BALTIMORE CITY PUBLIC SCHOOLS

ASTHMA IN THE PEDIATRIC POPULATION

Part D Pharmacy. An Independent Licensee of the Blue Cross Blue Shield Association ( )

COPD Medicine. No one ever showed me how to use this. Wendy Happel; RRT, COPD Educator Krystal Fedoris; RRT-NPS, BA, COPD Educator

The only sublingual grass allergy immunotherapy tablet with a mixed pollens allergen extract from 5 grasses 1

2017 Blue Cross and Blue Shield of Louisiana

Instructions for Use ALVESCO [ael- ves-koʊ] (ciclesonide) Inhalation Aerosol

Baltimore City Public Schools 2013 Dental Options

Transcription:

DRUG CLASS INHALATION BRAND NAME (generic) QUANTITY LIMIT CRITERIA SHORT ACTING BETA2-ADRENERGIC AGONIST ORAL (albuterol inhalation solution) PROAIR HFA PROAIR RESPICLICK PROVENTIL HFA VENTOLIN HFA XOPENEX SOLUTION XOPENEX CONCENTRATE XOPENEX HFA Status: CVS Caremark Criteria Type: Quantity Limit POLICY FDA-APPROVED INDICATIONS Albuterol Inhalation Solution 0.021% and 0.042% Albuterol sulfate inhalation solution 0.021% and 0.042% is indicated for the relief of bronchospasm in patients 2 to years of age with asthma (reversible obstructive airway disease). Albuterol Inhalation Solution 0.083% Albuterol sulfate inhalation solution 0.083% is indicated for the relief of bronchospasm in patients 2 years of age and older with reversible obstructive airway disease and acute attacks of bronchospasm. Beta Agonists-Short Acting Oral Inhalation Limit Policy CVS Caremark is an independent company that provides pharmacy benefit management services to CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. members. CareFirst BlueCross BlueShield is the shared business name of CareFirst of Maryland, Inc. and Group Hospitalization and Medical Services, Inc. CareFirst of Maryland, Inc., Group Hospitalization and Medical Services, Inc., CareFirst BlueChoice, Inc., The Dental Network and First Care, Inc. are independent licensees of the Blue Cross and Blue Shield Association. In the District of Columbia and Maryland, CareFirst MedPlus is the business name of First Care, Inc. In Virginia, CareFirst MedPlus is the business name of First Care, Inc. of Maryland (used in VA by: First Care, Inc.). Registered trademark of the Blue Cross and Blue Shield Association Page 1 of 5

Albuterol Inhalation Solution 0.5% Albuterol sulfate inhalation solution 0.5% is indicated for the relief of bronchospasm in patients 2 years of age and older with reversible obstructive airway disease and acute attacks of bronchospasm. ProAir HFA Proair HFA Inhalation Aerosol is indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease. Exercise-Induced Proair HFA Inhalation Aerosol is indicated for the prevention of exercise induced bronchospasm in patients 4 years of age and older. ProAir RespiClick ProAir RespiClick (albuterol sulfate) inhalation powder is indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease. Exercise-Induced ProAir RespiClick is indicated for the prevention of exercise-induced bronchospasm in patients 4 years of age and older. Proventil HFA Proventil HFA Inhalation Aerosol is indicated in adults and children 4 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm. Ventolin HFA Ventolin HFA is indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease. Exercise-Induced Ventolin HFA is indicated for the prevention of exercise-induced bronchospasm in patients 4 years of age and older. Solution (levalbuterol HCl) Inhalation Solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. Concentrate (levalbuterol HCl) Inhalation Solution Concentrate is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. HFA HFA is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 4 years of age and older with reversible obstructive airway disease. REFERENCES 1. Albuterol sulfate 0.63mg and 1.25mg inhalation solution [package insert]. Orlando, FL: Nephron Pharmaceuticals Corporation; March 2011. 2. Albuterol sulfate 0.63mg and 1.25mg inhalation solution [package insert]. Morgantown, WV: Mylan Pharmaceuticals Inc.; January 2013. 3. Albuterol sulfate 0.021% and 0.042% inhalation solution [package insert]. Corona, CA: Watson Laboratories Inc.; September 20. 4. Albuterol 0.083% inhalation solution [package insert]. E. Windsor, NJ: Aurobindo Pharma USA LLC; January 2017. Page 2 of 5

5. Albuterol 0.5% inhalation solution [package insert]. Tampa, FL: Bausch & Lomb Incorporated; February 2017. 6. Albuterol 0.5% inhalation solution [package insert]. Orlando, FL: Nephron Pharmaceuticals Corporation; November 2009. 7. Levalbuterol inhalation solution [package insert]. Princeton, NJ: Dr. Reddy's Laboratories, Inc.; September 2014. 8. ProAir HFA [package insert]. Horsham, PA: Teva Respiratory; July 2016. 9. ProAir RespiClick [package insert]. Horsham, PA: Teva Respiratory; September 2016. 10. Proventil HFA [package insert]. Whitehouse Station, NJ: Merck&Co., Inc.; December 2014. 11. Ventolin HFA [package insert]. Research Triangle Park, NC: GlaxoSmithKline; December 2014.. inhalation solution [package insert]. Marlborough, MA: Sunovion Pharmaceuticals, Inc.; January 2015. 13. inhalation solution, concentrate [package insert]. Marlborough, MA: Sunovion Pharmaceuticals, Inc.; January 2015. 14. HFA [package insert]. Marlborough, MA: Sunovion Pharmaceuticals, Inc.; February 2017. LIMIT CRITERIA PLEASE NOTE: Since manufacturer package sizes may vary, it is the discretion of the dispensing pharmacy to fill quantities per package size up to these quantity limits. In such cases the filling limit and day supply may be less than what is indicated. Medication* Albuterol 0.021%, 0.63mg / 3mL and 0.042%, 1.25mg / 3mL Inhalation Solution Albuterol 0.083%, 2.5mg / 3mL Inhalation Solution Maintenance Dose Maximum Daily Dose 4 vials (3mL 4 vials (3mL Package Size 60 vials (3mL 1 Month Limit* 3 Months Limit* 5 packages (5 15 packages (375 4 packages (0 packages (360 5 packages (5 15 packages (375 4 packages (0 packages (360 2 packages (0 6 packages (360 Page 3 of 5

Albuterol 0.5%, 2.5mg / 0.5mL Inhalation Solution ProAir HFA ProAir RespiClick Proventil HFA Ventolin HFA 0.31mg,0.63mg, 1.25 mg / 3 ml Levalbuterol Inhalation Solution Concentrate 1.25mg / 0.5mL HFA 0.25mL-0.5mL 1-2 1-2 1-2 1-2 three times 1 vial (0.5mL) three times 1-2 every 4 to 6 hours 2mL 3 vials (3mL 3 vials (0.5mL 20mL per bottle 30 vials (0.5mL 200 per 8.5gm 200 per inhaler 200 per 6.7gm 60 per 8gm 200 per 18gm 24 vials (3mL 30 vials (0.5mL 200 per 15gm 3 packages (20mL / 25 9 packages (20mL / 75 4 packages (0 vials x 0.5mL) / 25 packages (360vials x 0.5mL) / 75 2 packages (8.5gm / 25 6 packages (8.5gm / 75 2 packages / 25 6 packages / 75 2 packages (6.7gm / 25 6 packages (6.7gm / 75 6 packages (8gm / 25 18 packages (8gm / 75 2 packages (18gm / 25 6 packages (18gm / 75 4 packages (96 vials x 3mL) / 25 packages (288 4 packages (100 packages (300 3 packages (90 vials x 3mL) / 25 9 packages (270 3 package (90 vials x 0.5mL) / 25 9 packages (270 vials x 0.5mL) / 75 2 packages (15gm / 25 6 packages (15gm / 75 Page 4 of 5

*The duration of 25 is used for a 30-day fill period and 75 is used for a 90-day fill period to allow time for refill processing. *The limit criteria apply to both brand and generic, if available. Page 5 of 5